On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO).
Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease.
The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology.
Related: FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer.
The program is based on the original research agreement, established in 2019, which focused on a gene editing therapy for Hemophilia A.
2seventy bio will focus exclusively on the commercialization and continued development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in collaboration with Bristol Myers Squibb & Co (NYSE:BMY).
"We are pleased to announce the completion of this APA with Novo Nordisk as we believe it will provide the appropriate resources for both the team and the science behind this important program," said Chip Baird, CEO, 2seventy bio.
Under the terms of the agreement, 2seventy will potentially receive payments of up to $40 million.
2seventy will transfer the Hemophilia A program to Novo Nordisk, and the existing collaboration agreement will be terminated.
Additionally, the divestiture will include the transfer of 2seventy Bio's megaTAL technology and a license to the underlying intellectual property.
Price Action: TSVT shares are up 4.58% at $3.77 at last check Thursday.
週四,2seventy Bio Inc.(納斯達克股票代碼:TSVT)完成了與諾和諾德A/S(紐約證券交易所代碼:NVO)的資產購買協議。
根據條款,諾和諾德已經收購了血友病A項目和270ty體內基因編輯技術的版權,該技術不包括腫瘤學和用於自身免疫性疾病免疫細胞的自體或異基因細胞療法的基因編輯。
目前參與該計劃的270ty生物團隊將加入諾和諾德,繼續推進該技術的發展。
相關: 美國食品藥品管理局批准Bristol-Myers/2Seventy Bio的Abecma更早地用於預先治療的血液癌患者,並更新了有關繼發性癌症的方框警告。
該計劃基於2019年簽訂的最初研究協議,該協議側重於甲型血友病的基因編輯療法。
2seventy bio將專門專注於商業化和持續發展 Abecma (idecabtagene vicleucel), 其與Bristol Myers Squibb & Co(紐約證券交易所代碼:BMY)合作開發了針對多發性骨髓瘤的靶向BCMA的CAR T細胞療法。
2seventy bio首席執行官奇普·貝爾德表示:“我們很高興地宣佈與諾和諾德完成了這次APA,因爲我們相信這將爲該重要項目背後的團隊和科學提供適當的資源。”
根據協議條款,2seventy可能會獲得高達4000萬美元的付款。
2seventy將把A型血友病項目移交給諾和諾德,現有的合作協議將終止。
此外,資產剝離將包括轉讓2seventy Bio的MegaTal技術和基礎知識產權的許可。
價格走勢:週四最後一次檢查時,TSVT股價上漲4.58%,至3.77美元。